All News

A pharmacy that truly differentiates itself may create a niche that the giant online retailer would have trouble encroaching upon.

An emerging area of investigation in asthma and chronic obstructive pulmonary disease is use of statins.

Combining pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate (ORR) of 41% in patients with advanced non–small cell lung cancer (NSCLC), according to findings from an early phase study presented at the 2018 ASCO Annual meeting.

Top news of the day from across the health care landscape.

Rituximab (Rituxan) and lenalidomide (Revlimid) showed similar efficacy to rituximab plus chemotherapy, according to findings presented at the 2018 ASCO Annual Meeting.

Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non–small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

American Society of Health-System Pharmacists board votes unanimously to create a new section of practitioners that will help members provide optimal patient care and medication therapy management in specialty pharmacy.

Top news of the day from across the health care landscape.

Medication nonadherence in the United States reportedly costs the health care system $300 billion annually, but is this figure accurate?

Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.

The FDA has approved baricitinib (Olumiant), a once-daily oral drug for adults with moderately-to-severely active rheumatoid arthritis.

An extension trial assesses the efficacy and safety of extending edaravone treatment past the FDA-approved 6 cycles.

Studies explore the efficacy and safety of anticoagulation for atrial fibrillation in hemodialysis.

When individuals who are at risk for HIV use PrEP, and use it appropriately, risk of infection is significantly lowered.

Durvalumab, an FDA-approved immunotherapy, met its second primary endpoint of overall survival in the phase 3 PACIFIC trial for stage 3 non-small cell lung cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from The American Journal of Pharmacy Benefits.

Top news of the week from Specialty Pharmacy Times.

Those with hypertension had roughly 2.5 times more inpatient costs, almost twice the outpatient cost, and roughly triple the prescription medication cost annually.

New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.

What role do pharmacists play in medication optimization to help save money?

New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.

Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, and Specialty Pharmacy Times, the most read publication among specialty pharmacists, have been honored with the 2018 Hermes Creative Awards.

Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, and Specialty Pharmacy Times, the most read publication among specialty pharmacists, have been honored with the 2018 Hermes Creative Awards.

Researchers have published a review article in the journal Aging Male that implicates folic acid as a contributing factor in erectile dysfunction.

Ibrutinib plus obintuzumab improved progression-free survival in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The American Cancer Society (ACS) has updated its colorectal cancer (CRC) screening guidelines to lower the age at which individuals are recommended to begin screening.